Esperion's Q2 Product Sales Soar, But Collaboration Revenue Plummets

TL;DR

**ESPR's product sales are finally picking up, but the massive drop in collaboration revenue and widening losses mean this stock is still a high-risk bet.**

AI Summary

Esperion Therapeutics, Inc. reported a significant increase in product sales, reaching $40.274 million for the three months ended June 30, 2025, up from $28.302 million in the same period of 2024, representing a 42.3% increase. However, total revenues for the six months ended June 30, 2025, decreased to $147.380 million from $211.569 million in 2024, primarily due to a substantial drop in collaboration revenue from $158.511 million to $72.193 million. The company's net loss widened to $53.180 million for the six months ended June 30, 2025, compared to a net loss of $0.903 million in the prior year, driven by increased cost of goods sold (up 133.1% to $60.081 million) and higher interest expense (up 44.0% to $39.917 million). Cash and cash equivalents declined from $144.761 million at December 31, 2024, to $86.061 million at June 30, 2025. Strategic outlook includes expanded FDA and EC approvals for NEXLETOL/NEXLIZET and NILEMDO/NUSTENDI in March and May 2024, respectively, and anticipated approvals in Japan, Canada, Israel, and Australia through 2026, which could boost future collaboration revenue and product sales.

Why It Matters

Esperion's ability to significantly grow product sales by 42.3% in Q2 2025 demonstrates strong market penetration for NEXLETOL and NEXLIZET, which is crucial for long-term viability. However, the sharp decline in collaboration revenue and widening net loss to $53.180 million raises concerns about the sustainability of their business model and reliance on one-time partnership payments. Investors need to weigh the positive commercial traction against the increasing burn rate and the competitive landscape of cardiovascular disease treatments, where larger pharmaceutical companies like Amgen and Novartis also operate. This mixed performance could lead to increased volatility in ESPR stock as the market digests these conflicting signals.

Risk Assessment

Risk Level: high — Esperion reported a net loss of $53.180 million for the six months ended June 30, 2025, a significant increase from $0.903 million in the prior year. Cash and cash equivalents decreased by $58.700 million in the six months, from $144.761 million to $86.061 million, indicating a rapid cash burn. The company also has a total stockholders' deficit of $433.509 million, up from $388.722 million at December 31, 2024, highlighting substantial accumulated losses and a precarious financial position.

Analyst Insight

Investors should closely monitor Esperion's cash burn rate and the trajectory of collaboration revenue in upcoming quarters. While product sales growth is positive, the company's widening net loss and declining cash reserves suggest a need for further financing or a significant increase in profitability to avoid future dilution or liquidity issues. Consider a 'wait and see' approach for now.

Financial Highlights

debt To Equity

N/A

revenue

$147.380M

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$53.180M

eps

N/A

gross Margin

N/A

cash Position

$86.061M

revenue Growth

-30.3%

Revenue Breakdown

Key Numbers

• $40.274M — Product sales, net (Q2 2025) (Increased 42.3% from $28.302M in Q2 2024)
• $72.193M — Collaboration revenue (6 months ended June 30, 2025) (Decreased from $158.511M in the prior year)
• $147.380M — Total Revenues (6 months ended June 30, 2025) (Decreased from $211.569M in the prior year)
• $53.180M — Net loss (6 months ended June 30, 2025) (Widened from $0.903M in the prior year)
• $86.061M — Cash and cash equivalents (June 30, 2025) (Decreased from $144.761M at December 31, 2024)
• $433.509M — Total stockholders' deficit (June 30, 2025) (Increased from $388.722M at December 31, 2024)
• 201,622,825 — Common Stock Shares Outstanding (August 8, 2025) (Indicates potential for further dilution)

Key Players & Entities

• Esperion Therapeutics, Inc. (company) — registrant
• NEXLETOL (company) — lead product
• NEXLIZET (company) — lead product
• FDA (regulator) — approving body
• European Commission (regulator) — approving body
• Otsuka Pharmaceutical Co., Ltd (company) — Japanese collaborator
• Daiichi Sankyo Europe GmbH (company) — collaboration partner
• Daiichi Sankyo Co. Ltd (company) — collaboration partner
• NASDAQ Stock Market LLC (company) — exchange where common stock is registered

FAQ

Risk Factors

• Declining Cash Reserves [high — financial]: Cash and cash equivalents decreased from $144.761 million at December 31, 2024, to $86.061 million at June 30, 2025. This significant burn rate, coupled with a widening net loss of $53.180 million for the six months ended June 30, 2025, raises concerns about the company's ability to fund ongoing operations and future growth initiatives without additional capital.
• Increasing Net Loss and Operating Expenses [high — financial]: The company reported a net loss of $53.180 million for the six months ended June 30, 2025, a substantial increase from $0.903 million in the prior year. This widening loss is driven by a 133.1% increase in cost of goods sold to $60.081 million and a 44.0% increase in interest expense to $39.917 million.
• Growing Stockholders' Deficit [medium — financial]: Total stockholders' deficit increased from $388.722 million at December 31, 2024, to $433.509 million at June 30, 2025. This indicates that the company's liabilities exceed its assets, a persistent financial challenge.
• Dependence on Collaboration Revenue [high — market]: The significant drop in collaboration revenue from $158.511 million to $72.193 million for the six months ended June 30, 2025, highlights a key vulnerability. Future financial performance is heavily reliant on securing and maintaining these partnerships.
• FDA and EC Approval Dependency [medium — regulatory]: While the company has achieved expanded FDA and EC approvals for NEXLETOL/NEXLIZET and NILEMDO/NUSTENDI, future revenue growth is contingent on obtaining approvals in Japan, Canada, Israel, and Australia through 2026. Delays or failures in these approvals could negatively impact revenue projections.
• Increased Cost of Goods Sold [high — operational]: The cost of goods sold surged by 133.1% to $60.081 million for the six months ended June 30, 2025. This dramatic increase impacts gross margins and profitability, requiring careful management of production and supply chain costs.
• Rising Interest Expense [medium — financial]: Interest expense increased by 44.0% to $39.917 million for the six months ended June 30, 2025. This rise in financing costs further contributes to the widening net loss and puts pressure on the company's bottom line.
• Potential for Stock Dilution [medium — financial]: With 201,622,825 common stock shares outstanding as of August 8, 2025, the company may need to issue additional shares to raise capital, potentially diluting existing shareholders' ownership.

Industry Context

The cardiovascular drug market is highly competitive, with established players and ongoing innovation. Esperion operates in this space with its cholesterol-lowering therapies. Key trends include the increasing focus on preventative care, the development of novel mechanisms of action, and the impact of regulatory approvals on market access and commercialization.

Regulatory Implications

Esperion's growth strategy is heavily reliant on securing regulatory approvals in new international markets, including Japan, Canada, Israel, and Australia, through 2026. Delays or rejections in these processes could significantly hinder revenue expansion and impact the company's financial outlook.

What Investors Should Do

1. Monitor collaboration revenue trends closely.
2. Analyze the drivers of increased Cost of Goods Sold.
3. Evaluate the company's cash burn rate and future financing needs.
4. Assess the impact of international regulatory approvals on future revenue.

Key Dates

• 2024-03-01: Expanded FDA and EC approvals for NEXLETOL/NEXLIZET — Broadens market access and potential for product sales growth.
• 2024-05-01: Expanded FDA and EC approvals for NILEMDO/NUSTENDI — Increases commercial opportunities for key product lines.
• 2025-06-30: End of Q2 2025 — Reporting period for the 10-Q, showing significant revenue shifts and increased net loss.
• 2025-08-08: Common Stock Shares Outstanding reported — Provides context for potential future dilution and market capitalization.
• 2026-12-31: Anticipated approvals in Japan, Canada, Israel, and Australia — Key milestones for future revenue growth through international expansion.

Glossary

Stockholders' Deficit

The amount by which total liabilities exceed total assets, indicating a negative net worth. (Esperion's stockholders' deficit increased to $433.509 million as of June 30, 2025, highlighting ongoing financial challenges.)

Cost of Goods Sold (COGS)

The direct costs attributable to the production of the goods sold by a company. (A significant 133.1% increase in COGS for Esperion impacted profitability in the first half of 2025.)

Collaboration Revenue

Revenue generated from partnerships and agreements with other companies, often involving licensing or co-development. (Esperion experienced a substantial decline in collaboration revenue, a key component of its total revenue.)

Net Loss

The total expenses incurred by a company exceed its total revenues over a specific period. (Esperion's net loss widened significantly in the first six months of 2025, indicating increased operational costs and reduced revenue streams.)

Cash and Cash Equivalents

Highly liquid short-term investments that can be readily converted into cash. (Esperion's cash position decreased substantially, raising concerns about its liquidity and ability to fund operations.)

Year-Over-Year Comparison

Esperion Therapeutics reported a mixed financial performance compared to the prior year. While product sales saw a robust 42.3% increase in Q2 2025, total revenues for the six-month period declined due to a sharp drop in collaboration revenue. The company's net loss widened significantly, driven by a substantial increase in the cost of goods sold and higher interest expenses. Cash reserves have also diminished, indicating increased operational costs and a greater need for careful financial management.

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 per share ESPR NASDAQ Stock Market LLC

Filing Documents

• espr-20250630.htm (10-Q) — 1064KB
• espr-ex311x06302025.htm (EX-31.1) — 11KB
• espr-ex312x06302025.htm (EX-31.2) — 11KB
• espr-ex321x06302025.htm (EX-32.1) — 8KB
• 0001628280-25-040139.txt ( ) — 6726KB
• espr-20250630.xsd (EX-101.SCH) — 62KB
• espr-20250630_cal.xml (EX-101.CAL) — 55KB
• espr-20250630_def.xml (EX-101.DEF) — 277KB
• espr-20250630_lab.xml (EX-101.LAB) — 718KB
• espr-20250630_pre.xml (EX-101.PRE) — 481KB
• espr-20250630_htm.xml (XML) — 774KB

— FINANCIAL INFORMATION

PART I — FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements Condensed Balance Sheets at June 3 0 , 2025 and December 31, 2024 3 Condensed Statements of Operations and Comprehensive (Loss) Income for the three and six month periods ended June 30 , 2025 and 2024 4 Condensed Statements of Stockholders' Deficit for the three and six month periods ended June 30 , 2025 and 2024 5 Condensed Statements of Cash Flows for the six month periods ended June 30 , 2025 and 2024 6 Notes to Condensed Financial Statements 7

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 29

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 39

Controls and Procedures

Item 4. Controls and Procedures 40

— OTHER INFORMATION

PART II — OTHER INFORMATION

Legal Proceedings

Item 1. Legal Proceedings 41

Risk Factors

Item 1A. Risk Factors 41

Other Information

Item 5. Other Information 45

Exhibits

Item 6. Exhibits 46

Signatures

Signatures 47 From time to time, we may use our website, our X (formerly Twitter) account (@EsperionInc) or our LinkedIn profile at www.linkedin.com/company/esperion-therapeutics to distribute material information. Our financial and other material information is routinely posted to and accessible on the Investors & Media section of our website, available at www.esperion.com. Investors are encouraged to review the Investors & Media section of our website because we may post material information on that site that is not otherwise disseminated by us. Information that is contained in and can be accessed through our website or our LinkedIn page is not incorporated into, and does not form a part of, this Quarterly Report on Form 10-Q. We use various trademarks and trade names in our business, including without limitation our corporate name and logo. This Quarterly Report on Form 10-Q may also contain trademarks, service marks and trade names of third parties, which are the property of their respective owners. Our use or display of third parties' trademarks, service marks, trade names or products in this Quarterly Report on Form 10-Q is not intended to, and does not imply a relationship with, or endorsement or sponsorship by us. Solely for convenience, the trademarks and trade names in this Quarterly Report on Form 10-Q may be referred to without the and symbols, but the omission of such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. 2 Table of Contents Esperion Therapeutics, Inc. Condensed Balance Sheets (in thousands, except share data) June 30, 2025 December 31, 2024 (unaudited) Assets Current assets: Cash and cash equivalents $ 86,061 $ 144,761 Accounts receivable, net 107,746 80,142 Inventories, net 114,466 94,491 Prepaid clinical development costs 4,170 586 Prepaid inventory costs 24,772 13,863 Other prepaid and current assets 5

View Full Filing

View this 10-Q filing on SEC EDGAR